Evidence map›Paper›PMID 27922176›Full record

ArticleBritish journal of pharmacology2017

Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.

Grazia Esposito, Donato Cappetta, Rosa Russo, Alessia Rivellino, Loreta Pia Ciuffreda, Fiorentina Roviezzo, Elena Piegari, Liberato Berrino, Francesco Rossi, Antonella De Angelis and 1 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Developmental origins of immunometabolic health.Immunometabolism (Cobham, Surrey) · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Grazia EspositoDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Donato CappettaDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Rosa RussoDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Alessia RivellinoDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Loreta Pia CiuffredaDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Fiorentina RoviezzoDepartment of Pharmacy, University of Naples "Federico II", Naples, Italy.
Elena PiegariDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Liberato BerrinoDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Francesco RossiDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Antonella De AngelisDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
Konrad UrbanekDepartment of Experimental Medicine, Section of Pharmacology, Univesity of Campania "Luigi Vanvitelli", Naples, Italy.
University of Campania "Luigi Vanvitelli" · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeHeart failure with preserved ejection fraction (HFpEF) is a systemic syndrome driven by co-morbidities, and its pathophysiology is poorly understood. Several studies suggesting that dipeptidyl peptidase 4 (DPP4) might be involved in the pathophysiology of heart failure have prompted experimental and clinical investigations of DPP4 inhibitors in the cardiovascular system. Here we have investigated whether the DPP4 inhibitor sitagliptin affected the progression of HFpEF independently of its effects on glycaemia. EXPERIMENTAL APPROACH: Seven-week-old Dahl salt-sensitive rats were fed a high-salt diet for 5 weeks to induce hypertension. Then the rats continued with the high-salt diet and were treated with either sitagliptin (10 mg·kg KEY

resultsTreatment with sitagliptin attenuated diastolic dysfunction, reduced mortality and reduced cardiac DPP4 activity, along with increased circulating GLP-1 and myocardial expression of GLP-1 receptors. Myocardial levels of pro-inflammatory cytokines (TNF-α, IL-6 and CCL2) were reduced. Sitagliptin treatment decreased the levels of endothelial NOS monomer, responsible for generation of ROS, while the amount of NO-producing dimeric form increased. Markers of oxidative and nitrosative stress were decreased. Moreover, increased collagen deposition and activation of pro-fibrotic signalling, inducing elevated myocardial stiffness, were attenuated by sitagliptin treatment. CONCLUSIONS AND IMPLICATIONS: Sitagliptin positively modulated active relaxation and passive diastolic compliance by decreasing inflammation-related endothelial dysfunction and fibrosis, associated with HFpEF. LINKED ARTICLES: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.

Indexed as

AnimalsAnti-Inflammatory AgentsBlood PressureDiastoleDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsFibrosisGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHeartHeart FailureMaleMyocardiumNitric OxideRats, Inbred DahlSitagliptin PhosphateAnti-Inflammatory AgentsDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDPP4 protein, ratGlp1r protein, ratGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorNitric OxideSitagliptin Phosphate

Identifiers

PMID27922176
PMCPMC5659996
OpenAlexW2783210337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.